INCY Incyte Corporation Stock Quote

INCY [NASD]

Index	S&P 500	P/E	18.06	EPS (ttm)	4.20	Insider Own	0.40%	Shs Outstand	221.33M	Perf Week	2.90%
Market Cap	16.08B	Forward P/E	16.68	EPS next Y	4.55	Insider Trans	-	Shs Float	218.09M	Perf Month	-1.68%
Income	933.00M	PEG	1.21	EPS next Q	0.74	Inst Own	95.50%	Short Float	2.59%	Perf Quarter	-4.79%
Sales	3.11B	P/S	5.16	EPS this Y	415.00%	Inst Trans	1.63%	Short Ratio	3.91	Perf Half Y	3.53%
Book/sh	17.45	P/B	4.35	EPS next Y	41.69%	ROA	20.60%	Target Price	91.86	Perf Year	-10.40%
Cash/sh	12.01	P/C	6.32	EPS next 5Y	14.90%	ROE	27.20%	52W Range	61.91 - 85.97	Perf YTD	3.39%
Dividend	-	P/FCF	26.39	EPS past 5Y	51.40%	ROI	25.30%	52W High	-11.73%	Beta	0.67
Dividend %	-	Quick Ratio	3.70	Sales past 5Y	22.00%	Gross Margin	95.40%	52W Low	22.58%	ATR	2.19
Employees	2094	Current Ratio	3.70	Sales Q/Q	21.30%	Oper. Margin	19.40%	RSI (14)	54.92	Volatility	2.49% 2.87%
Optionable	Yes	Debt/Eq	0.01	EPS Q/Q	-29.40%	Profit Margin	30.00%	Rel Volume	0.49	Prev Close	75.63
Shortable	Yes	LT Debt/Eq	0.01	Earnings	May 03 BMO	Payout	0.00%	Avg Volume	1.44M	Price	75.89
Recom	2.10	SMA20	3.88%	SMA50	1.39%	SMA200	5.51%	Volume	706,596	Change	0.34%

Feb-09-22

Downgrade

SVB Leerink

Mkt Perform → Underperform

$60 → $56

Jan-18-22

Upgrade

RBC Capital Mkts

Sector Perform → Outperform

$78 → $90

Nov-19-21

Initiated

BMO Capital Markets

Market Perform

$75

Jul-20-21

Upgrade

The Benchmark Company

Hold → Buy

$89

Feb-10-21

Downgrade

SVB Leerink

Mkt Perform → Underperform

$70

Jan-07-21

Initiated

Truist

Buy

$120

Jan-04-21

Upgrade

Guggenheim

Neutral → Buy

Jun-16-20

Initiated

The Benchmark Company

Hold

May-06-20

Downgrade

JP Morgan

Overweight → Neutral

$89 → $99

Apr-29-20

Downgrade

Morgan Stanley

Overweight → Equal-Weight

$94

Apr-01-20

Upgrade

Morgan Stanley

Equal-Weight → Overweight

$83 → $90

Mar-24-20

Resumed

William Blair

Outperform

Mar-13-20

Upgrade

BofA/Merrill

Neutral → Buy

$83

Feb-04-20

Resumed

BofA/Merrill

Neutral

$82

Jan-03-20

Reiterated

BMO Capital Markets

Market Perform

$85 → $74

Jan-03-20

Downgrade

Mizuho

Buy → Neutral

$98 → $79

Jan-02-20

Downgrade

Guggenheim

Buy → Neutral

Oct-03-19

Initiated

Mizuho

Buy

$95

Sep-12-19

Initiated

BMO Capital Markets

Market Perform

Sep-05-19

Upgrade

Oppenheimer

Perform → Outperform

$100

Jun-29-22 06:17AM	Incyte (NASDAQ:INCY) shareholders are up 3.4% this past week, but still in the red over the last five years Simply Wall St.
Jun-26-22 07:45AM	3 Cheap Growth Stocks Near Their 52-Week Lows to Buy and Forget Motley Fool
Jun-17-22 05:00AM	Fastest-growing public companies: Revenue spikes for Waltham cancer drug firm American City Business Journals
Jun-14-22 11:00AM	MorphoSys (MOR) Gains on Oncology Collaboration With Pfizer Zacks
10:41AM	Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata Zacks
Jun-13-22 09:50PM	FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata PR Newswire
Jun-07-22 03:25PM	Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year Zacks
Jun-02-22 01:24PM	Top Analyst Reports for Broadcom, Intel & Union Pacific Zacks
11:31AM	Why Is Incyte (INCY) Down 7.1% Since Last Earnings Report? Zacks
May-26-22 06:00AM	Data from Incytes Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting Business Wire
May-24-22 08:00AM	Incyte to Present at Upcoming Investor Conference Business Wire
May-23-22 11:33AM	Lilly's (LLY) Olumiant Gets CHMP Nod for Alopecia Areata Zacks
May-20-22 02:53PM	CHMP Backs Approval of Lilly/Incyte's Olumiant For Patchy Hair Loss Benzinga
02:06PM	Eli Lilly Gets Positive Opinion for Olumiant in Europe. The Stock Rises. Barrons.com
08:11AM	CHMP Recommends Approval of Lilly and Incyte's OLUMIANT® (baricitinib) as the First and Only Centrally-Authorized Treatment for Adults with Severe Alopecia Areata (AA) PR Newswire
May-18-22 11:23AM	2 Under-the-Radar Biotech Stocks to Buy in 2022 Motley Fool
May-13-22 01:49PM	Mizuho Sees Relief For This Small-Cap Stock After Patent Legal Overhang Lifted Benzinga
12:19PM	Why CTI Biopharma Stock Is Surging Today Motley Fool
May-12-22 08:02AM	Lilly's (LLY) Olumiant Gets Full Approval From FDA for COVID Zacks
May-11-22 07:04AM	FDA approves Eli Lilly and Incyte's Olumiant for treatment of certain hospitalized adults with COVID-19 MarketWatch
06:45AM	FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) for the Treatment of Certain Hospitalized Patients with COVID-19 PR Newswire
May-05-22 01:20AM	Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease Business Wire
May-04-22 04:15PM	Incyte to Present at Upcoming Investor Conference Business Wire
May-03-22 02:05PM	Despite Q1 Earnings Miss, Incyte Shares Jump On Revised FY22 Sales Guidance Benzinga
11:53AM	Incyte's (INCY) Q1 Earnings and Revenues Fall Shy of Estimates Zacks
08:25AM	Incyte (INCY) Lags Q1 Earnings and Revenue Estimates Zacks
07:00AM	Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire
May-02-22 03:55PM	Drug/Biotech Stocks Q1 Earnings Due on May 3: PFE, BIIB & More Zacks
May-01-22 06:15AM	3 Nasdaq Stocks to Buy Now for Growth InvestorPlace
Apr-28-22 04:05PM	Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan Business Wire
Apr-27-22 12:17PM	Incyte (INCY) to Report Q1 Earnings: What's in the Cards? Zacks
Apr-26-22 03:01PM	Earnings Preview: Incyte (INCY) Q1 Earnings Expected to Decline Zacks
Apr-25-22 01:16PM	Novartis (NVS) Gets Positive CHMP Opinion on Lung Cancer Drug Zacks
Apr-22-22 12:00PM	EMA's Advisory Committee Backs Approval Of Incyte's Capmatinib In Advanced Lung Cancer Setting Benzinga
09:40AM	Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer Business Wire
Apr-20-22 11:03AM	Incyte Corporation's (NASDAQ:INCY) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason? Simply Wall St.
Apr-12-22 08:00AM	Incyte to Report First Quarter Financial Results Business Wire
Apr-05-22 02:55PM	Incyte's new 200,000-square-foot building will bring more workers to Wilmington HQ American City Business Journals
Mar-28-22 10:12AM	Incyte's Ruxolitinib Shows Further Improvement In Facial, Total Body Re-pigmentation At 52 Weeks In Skin Disorder Benzinga
Mar-26-22 11:20AM	Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly's Pivotal Phase 3 Studies PR Newswire
10:40AM	Incyte Announces 52-Week Data From the Phase 3 TRuE-V Program Evaluating Ruxolitinib Cream (Opzelura) in Patients With Vitiligo Business Wire
Mar-25-22 08:30AM	Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease Business Wire
Mar-24-22 11:00AM	2 Healthcare Stocks You Can Buy and Hold for the Next Decade Motley Fool
Mar-23-22 07:05AM	MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland Benzinga
Mar-18-22 09:56AM	Incyte Announces Multiple Abstracts from its Dermatology Portfolio have been Accepted for Presentation at the 2022 American Academy of Dermatology (AAD) Annual Meeting Business Wire
09:15AM	AbbVie's (ABBV) Rinvoq Gets FDA Nod for Ulcerative Colitis Zacks
09:10AM	Incyte's (INCY) Going Gets Tough Due to Pipeline Setbacks Zacks
Mar-16-22 12:32PM	Biotech Stock Roundup: NKTR Plunges on Study Failure, MRNA Offers Updates & More Zacks
Mar-15-22 11:37AM	Incyte (INCY) Label Expansion for Ruxolitinib Cream Delayed Zacks
Mar-14-22 08:00AM	Incyte Announces U.S. FDA Has Extended the Supplemental New Drug Application Review Period for Ruxolitinib Cream (Opzelura) for the Treatment of Vitiligo Business Wire
Mar-10-22 11:30AM	Why Is Incyte (INCY) Up 5.5% Since Last Earnings Report? Zacks
Mar-04-22 10:50AM	Preliminary U.K. research says Lilly drug can reduce the risk of death among severely ill COVID-19 patients MarketWatch
Mar-03-22 03:37PM	Hospitalized Covid-19 Patients Can Gain From Lilly Arthritis Drug, Data Show Barrons.com
12:54PM	Eli Lilly's JAK Inhibitor Baricitinib Cuts Death Risk By 13% In COVID-19 Patients Benzinga
Mar-01-22 07:55AM	Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer GlobeNewswire
Feb-18-22 08:30PM	US Ecology, Incyte, and Other Stocks See Action From Activist Investors Barrons.com
03:16PM	7 Insider Stocks to Buy as Execs Snap Them Up InvestorPlace
Feb-15-22 08:00AM	Incyte to Present at Upcoming Investor Conference Business Wire
Feb-09-22 07:38AM	New Strong Sell Stocks for February 9th Zacks
Feb-08-22 12:24PM	Why Are Incyte Shares Trading Lower Today? Benzinga
11:01AM	Incyte (INCY) Q4 Earnings Miss, Sales Beat on Jakafi, Royalties Zacks
07:00AM	Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guidance and Updates on Key Clinical Programs Business Wire
06:44AM	The SEC is pushing the limits of insider trading enforcement Fortune
Feb-07-22 09:53AM	Drug/Biotech Stock Q4 Earnings Due Feb 8: PFE, INCY & DCPH Zacks
09:38AM	McCarthy Asset Management, Inc. Buys ARK Innovation ETF, Parker Hannifin Corp, Adient PLC, ... GuruFocus.com
Feb-06-22 03:37PM	Did The Smart Money Get Incyte Corporation (INCY) Right? Insider Monkey
Feb-03-22 05:38PM	Todd Asset Management Llc Buys Seagate Technology Holdings PLC, Lowe's Inc, Zions Bancorp NA, ... GuruFocus.com
01:38PM	Eli Lilly (LLY) Q4 Earnings Miss, COVID Therapies Aid Sales Zacks
10:07AM	Incyte (INCY) to Report Q4 Earnings: What's in the Offing? Zacks
08:00AM	Incyte to Present at Upcoming Investor Conference Business Wire
Jan-31-22 11:19AM	Lilly (LLY) Stops Lupus Study, Expects CRL for Olumiant in Eczema Zacks
Jan-28-22 11:04AM	Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema Benzinga
08:00AM	Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis PR Newswire
Jan-27-22 10:27AM	Biotech Stock Roundup: VRTX Q4 Earnings, GILD, INCYs Regulatory Updates & More Zacks
Jan-26-22 07:07AM	Incyte Pulls Parsaclisib US Application For Lymphoma Treatment, Bows Out Solid Tumor Program With Merus Benzinga
Jan-25-22 04:30PM	Merus Appoints Shannon Campbell as Chief Commercial Officer and Regains Worldwide Rights to MCLA-145 GlobeNewswire
04:30PM	Incyte Provides Update on Parsaclisib and MCLA-145 Business Wire
11:00AM	2 Beaten-Down Cathie Wood Growth Stocks to Buy and Hold For 10 Years Motley Fool
Jan-21-22 01:38PM	Shikiar Asset Management Inc Buys Warby Parker Inc, Compass Diversified Holdings, RLJ Lodging ... GuruFocus.com
Jan-20-22 07:03AM	The past five years for Incyte (NASDAQ:INCY) investors has not been profitable Simply Wall St.
Jan-18-22 08:00AM	Incyte to Report Fourth Quarter and Year-End 2021 Financial Results Business Wire
Jan-06-22 05:38PM	Tributary Capital Management, LLC Buys LHC Group Inc, Cambium Networks Corp, Avanos Medical ... GuruFocus.com
Dec-16-21 08:36AM	Lilly (LLY) Stock Up on Raised 2021 View, Upbeat 2022 Guidance Zacks
Dec-15-21 09:06AM	Incyte's Topical JAK Inhibitor Under Priority FDA Review For Depigmented Skin Disorder Benzinga
Dec-14-21 04:30PM	Incyte Announces Acceptance and Priority Review of sNDA for Ruxolitinib Cream (Opzelura) as a Treatment for Patients with Vitiligo Business Wire
08:00AM	Incyte to Present at Upcoming Investor Conferences Business Wire
Dec-13-21 08:45PM	Airbnb, Lucid and 3 other Bay Area companies are joining the Nasdaq 100 American City Business Journals
12:55PM	Lucid shares higher as company joins Nasdaq-100 index Yahoo Finance
Dec-11-21 12:00PM	MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi®) in Combination with Lenalidomide for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Business Wire
09:00AM	Incyte Announces Updated Data Demonstrating Rapid and Durable Responses of Parsaclisib in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas Business Wire
Dec-08-21 07:38PM	Tekla Healthcare Opportunities Fund Buys Moderna Inc, IDEXX Laboratories Inc, Sarepta ... GuruFocus.com
03:34PM	Here is What Hedge Funds Think About Incyte Corporation (INCY) Insider Monkey
Dec-06-21 10:04AM	AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label Zacks
Dec-02-21 11:31AM	Why Is Incyte (INCY) Down 2.7% Since Last Earnings Report? Zacks
Nov-09-21 08:30AM	OLUMIANT® Long-Term Safety Profile Established Up to 9.3 Years in Integrated Analysis of More Than 3,700 Patients with Rheumatoid Arthritis PR Newswire
08:00AM	Incyte to Present at Upcoming Investor Conference Business Wire
Nov-04-21 10:07AM	Cellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based Therapies PR Newswire
09:00AM	More than 35 Abstracts from Incytes Oncology Portfolio Accepted for Presentation at the 63rd Annual ASH Meeting and Exposition Business Wire
Nov-02-21 12:00PM	Incyte Corporation (INCY) Q3 2021 Earnings Call Transcript Motley Fool -8.46%
09:24AM	Incyte (INCY) Q3 Earnings & Sales Beat, Royalty Revenues Grow Zacks

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Flannelly Barry P	EVP & General Manager US	Apr 08	Option Exercise	70.48	41,864	2,950,628	88,640	Apr 12 04:10 PM
Flannelly Barry P	EVP & General Manager US	Apr 08	Sale	83.49	43,993	3,672,887	65,163	Apr 12 04:10 PM
BAKER BROS. ADVISORS LP	Director	Mar 10	Buy	73.13	218,563	15,982,720	33,419,055	Mar 10 06:02 PM
BAKER BROS. ADVISORS LP	Director	Mar 09	Buy	71.72	70,517	5,057,550	33,217,136	Mar 10 06:02 PM
BAKER BROS. ADVISORS LP	Director	Mar 08	Option Exercise	22.05	40,000	882,000	33,059,604	Mar 10 06:02 PM
BAKER BROS. ADVISORS LP	Director	Mar 08	Buy	70.67	100,000	7,067,500	33,151,989	Mar 10 06:02 PM
BAKER BROS. ADVISORS LP	Director	Feb 22	Buy	68.07	99,800	6,793,536	33,039,604	Feb 22 05:45 PM
BAKER BROS. ADVISORS LP	Director	Feb 18	Buy	68.38	133,032	9,096,550	32,947,370	Feb 22 05:45 PM
BAKER BROS. ADVISORS LP	Director	Feb 17	Buy	67.74	292,972	19,844,805	32,824,461	Feb 22 05:45 PM
Dickinson Jonathan Elliott	EVP, General Manager, Europe	Jan 31	Sale	74.19	7,375	547,151	30,214	Feb 02 04:25 PM
SWAIN PAULA J	EVP, Human Resources	Jan 07	Option Exercise	73.21	10,870	795,793	83,241	Jan 11 04:18 PM
SWAIN PAULA J	EVP, Human Resources	Jan 07	Sale	73.31	10,870	796,880	72,371	Jan 11 04:18 PM
SWAIN PAULA J	EVP, Human Resources	Jan 04	Option Exercise	73.21	9,319	682,244	81,690	Jan 05 04:25 PM
SWAIN PAULA J	EVP, Human Resources	Jan 04	Sale	73.46	9,319	684,574	72,371	Jan 05 04:25 PM
Trower Paul	Principal Accounting Officer	Jan 03	Option Exercise	73.21	8,214	601,347	39,086	Jan 05 04:40 PM
Trower Paul	Principal Accounting Officer	Jan 03	Sale	73.31	8,214	602,168	32,268	Jan 05 04:40 PM
DIXON WENDY L	Director	Dec 23	Option Exercise	73.25	20,000	1,465,000	37,259	Dec 27 04:11 PM
DIXON WENDY L	Director	Dec 23	Sale	22.05	20,000	441,000	17,259	Dec 27 04:11 PM
BAKER BROS. ADVISORS LP	Director	Dec 17	Buy	72.80	1,075,872	78,322,148	30,932,696	Dec 17 06:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 16	Buy	71.96	169,315	12,184,411	29,856,824	Dec 17 06:30 PM
BAKER BROS. ADVISORS LP	Director	Dec 15	Buy	71.51	350,332	25,052,340	29,687,509	Dec 17 06:30 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Oct 01	Sale	68.67	389	26,713	31,263	Oct 04 04:41 PM
Pasquale Maria E	EVP & General Counsel	Sep 24	Option Exercise	65.36	382	24,968	36,187	Sep 28 08:18 AM
SWAIN PAULA J	EVP, Human Resources	Sep 20	Option Exercise	73.21	1,356	99,273	60,959	Sep 21 04:09 PM
Dhanak Dashyant	EVP & Chief Scientific Officer	Sep 01	Sale	76.71	388	29,763	31,652	Sep 03 07:40 AM
Dhanak Dashyant	EVP & Chief Scientific Officer	Aug 02	Sale	77.49	389	30,144	32,040	Aug 04 04:16 PM
Iyengar Vijay K	EVP GPS, BD, & Licensing	Jul 29	Sale	78.29	4,911	384,482	27,005	Aug 02 04:14 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience